Psoriasis - Pipeline Review, H1 2012

Global Markets Direct, February 2012, Pages: 267

Psoriasis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Psoriasis - Pipeline Review, H1 2012', provides an overview of the Psoriasis therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis. 'Psoriasis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Psoriasis.
- A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Psoriasis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Psoriasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Psoriasis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Psoriasis Therapeutic Products under Development, Key Players in Psoriasis Therapeutics, Psoriasis Pipeline Overview, Psoriasis Pipeline, Psoriasis Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Psoriasis Overview
Therapeutics Development
An Overview of Pipeline Products for Psoriasis
Psoriasis Therapeutics under Development by Companies
Psoriasis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Psoriasis Therapeutics – Products under Development by Companies
Psoriasis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Psoriasis Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Johnson & Johnson
Boehringer Ingelheim GmbH
Kyowa Hakko Kirin Co., Ltd.
Amgen Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Biotest AG
Merck & Co., Inc.
BioLineRx, Ltd.
ApoPharma
Celltrion, Inc.
Novartis AG
Isotechnika Pharma Inc.
Actelion Ltd
Astellas Pharma Inc.
Biocon Limited
Cephalon, Inc.
Dr. Reddy's Laboratories Limited
Eisai Co., Ltd.
Galderma S.A.
LEO Pharma A/S
Pfizer Inc.
Celgene Corporation
Incyte Corporation
4SC AG
3SBio Inc.
Addex Pharmaceuticals
InNexus Biotechnology Inc.
Can-Fite BioPharma Ltd.
Idera Pharmaceuticals, Inc.
Almirall, S.A.
Astralis, Ltd.
Lupin Limited
Basilea Pharmaceutica Ltd.
NexMed, Inc.
NicOx SA
CytoGenix, Inc.
CombinatoRx, Incorporated
Protalix BioTherapeutics, Inc.
Tolerx, Inc.
Genizon BioSciences, Inc.
Cytos Biotechnology AG
Biotie Therapies Corp.
Provectus Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Sareum Holdings plc
Hybrigenics S.A.
R-Tech Ueno, Ltd.
Piramal Life Sciences Limited
Paloma Pharmaceuticals, Inc.
D-Pharm Ltd.
Affimed Therapeutics AG
Viron Therapeutics, Inc.
Jenrin Discovery, Inc.
Probiodrug AG
Physica Pharma
Phenex Pharmaceuticals AG
MIKA Pharma GmbH
Cosmix Molecular Biologicals GmbH
CREABILIS Therapeutics S.r.l.
Anacor Pharmaceuticals, Inc.
JADO Technologies GmbH.
AnaptysBio, Inc.
Circassia Holdings Ltd.
Therapeutics Incorporated
Allozyne, Inc.
Oxagen Limited
S-BIO Pte Ltd
Vascular Biogenics Ltd.
Xention Limited
Virobay Inc.
Inimex Pharmaceuticals, Inc.
Welichem Biotech Inc.
ELORAC, Inc.
ChemoCentryx, Inc.
CBio Limited
SWITCH Biotech LLC
Laboratorios SALVAT S.A.
Maruho Co.,Ltd.
KAHR medical Ltd.
Cellceutix Pharmaceuticals, Inc.
Amplimmune, Inc.
Lycera Corp.
CalciMedica, Inc.
Femta Pharmaceuticals, Inc.
XBiotech USA, Inc.
Immune Technologies and Medicine
Mantecorp Industria Quimica e Farmaceutica Ltda
Psoriasis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BMS-582949 - Drug Profile
AMG 827 - Drug Profile
ASP0485 - Drug Profile
Hectorol - Drug Profile
ASP015K - Drug Profile
LY2439821 - Drug Profile
Tofacitinib - Drug Profile
CC-10004 - Drug Profile
LY3009104 - Drug Profile
CRx-197 - Drug Profile
AEB071 - Drug Profile
AIN457 - Drug Profile
Anti-CD6 Monoclonal Antibody - Drug Profile
BT-061 - Drug Profile
Ponesimod - Drug Profile
MK52 - Drug Profile
MK51 - Drug Profile
Toctino - Drug Profile
E6201 - Drug Profile
CT327 - Drug Profile
Stelara - Drug Profile
Voclosporin - Drug Profile
Jakafi - Drug Profile
CF101 - Drug Profile
PH-10 - Drug Profile
LEO 90100 - Drug Profile
LEO 22811 - Drug Profile
VB-201 - Drug Profile
WBI-1001 - Drug Profile
NPS31807 - Drug Profile
CD 2027 - Drug Profile
LL 4218 - Drug Profile
LAS41004 - Drug Profile
Psoraxine - Drug Profile
AN2728 - Drug Profile
CNTO 1959 - Drug Profile
GSK-2245840 - Drug Profile
STA-21 - Drug Profile
XToll - Drug Profile
Halobetasol Propionate - Drug Profile
Psorex - Drug Profile
Ketoconazole + UVB-Radiation - Drug Profile
LAS41002 - Drug Profile
Apremilast - Drug Profile
9-Cis-Beta-Carotene - Drug Profile
Prednisolone Acetate - Drug Profile
M518101 - Drug Profile
BFH772 - Drug Profile
Asord - Drug Profile
Halobetasol Proprionate Lotion - Drug Profile
COL-121 - Drug Profile
Pioglitazone - Drug Profile
FP-187 - Drug Profile
Etanercept - Drug Profile
Inecalcitol - Drug Profile
E-0116 - Drug Profile
Clobetasol Propionate + Etanercept - Drug Profile
Isotretinoin + NB-UVB - Drug Profile
MK-3222 - Drug Profile
LEO 90105 - Drug Profile
LEO 80185 Topical Suspension - Drug Profile
RA-18C3 - Drug Profile
Apo805K1 - Drug Profile
Psoriasis Therapeutics – Drug Profile Updates
Psoriasis Therapeutics – Discontinued Products
Psoriasis Therapeutics - Dormant Products
Psoriasis – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Psoriasis, H1 2012
Products under Development for Psoriasis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Development by Companies, H1 2012 (Contd..5)
Number of Products under Development by Companies, H1 2012 (Contd..6)
Number of Products under Development by Companies, H1 2012 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Development by Companies, H1 2012 (Contd..6)
Products under Development by Companies, H1 2012 (Contd..7)
Products under Development by Companies, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012
Bristol-Myers Squibb Company, H1 2012
Genzyme Corporation, H1 2012
Johnson & Johnson, H1 2012
Boehringer Ingelheim GmbH, H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Amgen Inc., H1 2012
Eli Lilly and Company, H1 2012
GlaxoSmithKline plc, H1 2012
Biotest AG, H1 2012
Merck & Co., Inc., H1 2012
BioLineRx, Ltd., H1 2012
ApoPharma, H1 2012
Celltrion, Inc., H1 2012
Novartis AG, H1 2012
Isotechnika Pharma Inc., H1 2012
Actelion Ltd, H1 2012
Astellas Pharma Inc., H1 2012
Biocon Limited, H1 2012
Cephalon, Inc., H1 2012
Dr. Reddy's Laboratories Limited, H1 2012
Eisai Co., Ltd., H1 2012
Galderma S.A., H1 2012
LEO Pharma A/S, H1 2012
Pfizer Inc., H1 2012
Celgene Corporation, H1 2012
Incyte Corporation, H1 2012
4SC AG, H1 2012
3SBio Inc., H1 2012
Addex Pharmaceuticals, H1 2012
InNexus Biotechnology Inc., H1 2012
Can-Fite BioPharma Ltd., H1 2012
Idera Pharmaceuticals, Inc., H1 2012
Almirall, S.A., H1 2012
Astralis, Ltd., H1 2012
Lupin Limited, H1 2012
Basilea Pharmaceutica Ltd., H1 2012
NexMed, Inc., H1 2012
NicOx SA, H1 2012
CytoGenix, Inc., H1 2012
CombinatoRx, Incorporated, H1 2012
Protalix BioTherapeutics, Inc., H1 2012
Tolerx, Inc., H1 2012
Genizon BioSciences, Inc., H1 2012
Cytos Biotechnology AG, H1 2012
Biotie Therapies Corp., H1 2012
Provectus Pharmaceuticals, Inc., H1 2012
Synta Pharmaceuticals Corp., H1 2012
Sareum Holdings plc, H1 2012
Hybrigenics S.A., H1 2012
R-Tech Ueno, Ltd., H1 2012
Piramal Life Sciences Limited, H1 2012
Paloma Pharmaceuticals, Inc., H1 2012
D-Pharm Ltd., H1 2012
Affimed Therapeutics AG, H1 2012
Viron Therapeutics, Inc., H1 2012
Jenrin Discovery, Inc., H1 2012
Probiodrug AG, H1 2012
Physica Pharma, H1 2012
Phenex Pharmaceuticals AG, H1 2012
MIKA Pharma GmbH, H1 2012
Cosmix Molecular Biologicals GmbH, H1 2012
CREABILIS Therapeutics S.r.l., H1 2012
Anacor Pharmaceuticals, Inc., H1 2012
JADO Technologies GmbH., H1 2012
AnaptysBio, Inc., H1 2012
Circassia Holdings Ltd., H1 2012
Therapeutics Incorporated, H1 2012
Allozyne, Inc., H1 2012
Oxagen Limited, H1 2012
S-BIO Pte Ltd, H1 2012
Vascular Biogenics Ltd., H1 2012
Xention Limited, H1 2012
Virobay Inc., H1 2012
Inimex Pharmaceuticals, Inc., H1 2012
Welichem Biotech Inc., H1 2012
ELORAC, Inc., H1 2012
ChemoCentryx, Inc., H1 2012
CBio Limited, H1 2012
SWITCH Biotech LLC, H1 2012
Laboratorios SALVAT S.A., H1 2012
Maruho Co.,Ltd., H1 2012
KAHR medical Ltd., H1 2012
Cellceutix Pharmaceuticals, Inc., H1 2012
Amplimmune, Inc., H1 2012
Lycera Corp., H1 2012
CalciMedica, Inc., H1 2012
Femta Pharmaceuticals, Inc., H1 2012
XBiotech USA, Inc., H1 2012
Immune Technologies and Medicine, H1 2012
Mantecorp Industria Quimica e Farmaceutica Ltda, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Psoriasis Therapeutics – Drug Profile Updates
Psoriasis Therapeutics – Discontinued Products
Psoriasis Therapeutics – Discontinued Products (Contd..1)
Psoriasis Therapeutics – Discontinued Products (Contd..2)
Psoriasis Therapeutics – Dormant Products
Psoriasis Therapeutics – Dormant Products (Contd..1)
Psoriasis Therapeutics – Dormant Products (Contd..2)
Psoriasis Therapeutics – Dormant Products (Contd..3)
Psoriasis Therapeutics – Dormant Products (Contd..4)
Psoriasis Therapeutics – Dormant Products (Contd..5)
Psoriasis Therapeutics – Dormant Products (Contd..6)
Psoriasis Therapeutics – Dormant Products (Contd..7)
Psoriasis Therapeutics – Dormant Products (Contd..8)
Psoriasis Therapeutics – Dormant Products (Contd..9)

List of Figures
Number of Products under Development for Psoriasis, H1 2012
Products under Development for Psoriasis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Alzheimer's Disease – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013
• Fungal Infections – Pipeline Review, H1 2013
• HIV-1 Infection – Pipeline Review, H1 2013
• Major Depressive Disorder – Pipeline Review, H1 2013
• Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2013
• Erectile Dysfunction – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013